Soichiro Ikeda

Fukuoka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

ZBP1 Protects Against mtDNA-Induced Myocardial Inflammation in Failing Hearts.

ZBP1 Protects Against mtDNA-Induced Myocardial Inflammation in Failing Hearts.

Journal: Circulation research

Published: March 28, 2023

Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity.

Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity.

Journal: JCI insight

Published: March 22, 2023

Immunomodulatory Cell Therapy Using αGalCer-Pulsed Dendritic Cells Ameliorates Heart Failure in a Murine Dilated Cardiomyopathy Model.

Immunomodulatory Cell Therapy Using αGalCer-Pulsed Dendritic Cells Ameliorates Heart Failure in a Murine Dilated Cardiomyopathy Model.

Journal: Circulation. Heart failure

Published: October 21, 2022

IFN-γ-STAT1-ERK Pathway Mediates Protective Effects of Invariant Natural Killer T Cells Against Doxorubicin-Induced Cardiomyocyte Death.

IFN-γ-STAT1-ERK Pathway Mediates Protective Effects of Invariant Natural Killer T Cells Against Doxorubicin-Induced Cardiomyocyte Death.

Journal: JACC. Basic to translational science

Published: January 26, 2022

Excessive Hypoxia-Inducible Factor-1α Expression Induces Cardiac Rupture via p53-Dependent Apoptosis After Myocardial Infarction.

Excessive Hypoxia-Inducible Factor-1α Expression Induces Cardiac Rupture via p53-Dependent Apoptosis After Myocardial Infarction.

Journal: Journal of the American Heart Association

Published: September 02, 2021

Heart Rate Reduction with Ivabradine Prevents Cardiac Rupture after Myocardial Infarction in Mice.

Heart Rate Reduction with Ivabradine Prevents Cardiac Rupture after Myocardial Infarction in Mice.

Journal: Cardiovascular drugs and therapy

Published: December 07, 2020

GFAT2 mediates cardiac hypertrophy through HBP-O-GlcNAcylation-Akt pathway.

GFAT2 mediates cardiac hypertrophy through HBP-O-GlcNAcylation-Akt pathway.

Journal: iScience

Published: September 23, 2020

Roxadustat Markedly Reduces Myocardial Ischemia Reperfusion Injury in Mice.

Roxadustat Markedly Reduces Myocardial Ischemia Reperfusion Injury in Mice.

Journal: Circulation journal : official journal of the Japanese Circulation Society

Published: March 28, 2020

DPP (Dipeptidyl Peptidase)-4 Inhibitor Attenuates Ang II (Angiotensin II)-Induced Cardiac Hypertrophy via GLP (Glucagon-Like Peptide)-1-Dependent Suppression of Nox (Nicotinamide Adenine Dinucleotide Phosphate Oxidase) 4-HDAC (Histone Deacetylase) 4 Pathway.

DPP (Dipeptidyl Peptidase)-4 Inhibitor Attenuates Ang II (Angiotensin II)-Induced Cardiac Hypertrophy via GLP (Glucagon-Like Peptide)-1-Dependent Suppression of Nox (Nicotinamide Adenine Dinucleotide Phosphate Oxidase) 4-HDAC (Histone Deacetylase) 4 Pathway.

Journal: Hypertension (Dallas, Tex. : 1979)

Published: March 12, 2020

Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity.

Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity.

Journal: JCI insight

Published: September 05, 2019

Blockade of L-type Ca2+ channel attenuates doxorubicin-induced cardiomyopathy via suppression of CaMKII-NF-κB pathway.

Blockade of L-type Ca2+ channel attenuates doxorubicin-induced cardiomyopathy via suppression of CaMKII-NF-κB pathway.

Journal: Scientific reports

Published: March 04, 2019

Malfunctioned cardiac resynchronization therapy attributed to acute exacerbation of cardiac sarcoidosis.

Malfunctioned cardiac resynchronization therapy attributed to acute exacerbation of cardiac sarcoidosis.

Journal: European heart journal

Published: May 27, 2016

Showing 1-12 of 12

Last Updated: 09/26/2026